Literature DB >> 24239845

oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4.

Yulia Kiyan1, Sergey Tkachuk2, Denise Hilfiker-Kleiner3, Hermann Haller4, Bianca Fuhrman5, Inna Dumler6.   

Abstract

The pathogenesis of atherosclerosis involves an imbalanced lipid metabolism and a deregulated immune response culminating in chronic inflammation of the arterial wall. Recent studies show that endogenous ligands, such as modified plasma lipoproteins, can trigger pattern recognition receptors (PRR) of innate immunity for cellular and humoral reactions. The underlying molecular pathways remain less explored. In this study, we investigated the mechanisms of inflammatory effects of oxidized low-density lipoproteins (oxLDL) on human primary coronary artery smooth muscle cells (VSMC). We show that already low concentration of oxLDL initiated atherogenic signals triggering VSMC transition to proinflammatory phenotype. oxLDL impaired the expression of contractile proteins and myocardin in VSMC and initiated changes in cell functional responses, including expression of proinflammatory molecules. The effects of oxLDL were abolished by downregulation of the multifunctional urokinase receptor (uPAR). In response to oxLDL uPAR associated with CD36 and TLR4, the two main PRR for both pathogen and endogenous ligands. We demonstrate that uPAR association with CD36 and TLR4 mediated oxLDL-induced and NF-κB-dependent G-CSF and GM-CSF expression and changes in VSMC contractile proteins. uPAR-mediated release of G-CSF and GM-CSF by VSMC affected macrophage behavior and production of MCP-1. We provide evidence for functional relevance of our in vitro findings to in vivo human atherosclerotic tissues. Our data imply uPAR as a part of a PRR cluster interfering structurally and functionally with CD36 and TLR4 and responding to endogenous atherogenic ligands. They further point to specific function of each component of this cluster in mediating the ultimate signaling pattern.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Inflammation; LDL; LPS; SMA; Urokinase receptor; VSMC; Vascular smooth muscle cells; lipopolysaccharide; low density lipoprotein; oxLDL; oxidated LDL; smooth muscle α actin; uPA; uPA receptor; uPAR; urokinase-type plasminogen activator; vascular smooth muscle cells

Mesh:

Substances:

Year:  2013        PMID: 24239845     DOI: 10.1016/j.yjmcc.2013.11.005

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  34 in total

Review 1.  An overview of potential molecular mechanisms involved in VSMC phenotypic modulation.

Authors:  Ming-Jie Zhang; Yi Zhou; Lei Chen; Yan-Qin Wang; Xu Wang; Yan Pi; Chang-Yue Gao; Jing-Cheng Li; Li-Li Zhang
Journal:  Histochem Cell Biol       Date:  2015-12-26       Impact factor: 4.304

Review 2.  Potential contributions of intimal and plaque hypoxia to atherosclerosis.

Authors:  Guo-Hua Fong
Journal:  Curr Atheroscler Rep       Date:  2015-06       Impact factor: 5.113

Review 3.  Lipopolysaccharide induced vascular smooth muscle cells proliferation: A new potential therapeutic target for proliferative vascular diseases.

Authors:  Dehua Jiang; Yu Yang; Dongye Li
Journal:  Cell Prolif       Date:  2017-02-02       Impact factor: 6.831

Review 4.  Angiotensin II and vascular injury.

Authors:  Augusto C Montezano; Aurelie Nguyen Dinh Cat; Francisco J Rios; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

Review 5.  The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease.

Authors:  Ying Zhou; Peter J Little; Liam Downey; Rizwana Afroz; Yuao Wu; Hang T Ta; Suowen Xu; Danielle Kamato
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-06

6.  Interaction of thrombospondin1 and CD36 contributes to obesity-associated podocytopathy.

Authors:  Wenpeng Cui; Hasiyeti Maimaitiyiming; Qi Zhou; Heather Norman; Changcheng Zhou; Shuxia Wang
Journal:  Biochim Biophys Acta       Date:  2015-03-31

7.  NF-κB, A Potential Therapeutic Target in Cardiovascular Diseases.

Authors:  Weijia Cheng; Can Cui; Gang Liu; Chenji Ye; Fang Shao; Ashim K Bagchi; Jawahar L Mehta; Xianwei Wang
Journal:  Cardiovasc Drugs Ther       Date:  2022-07-07       Impact factor: 3.727

Review 8.  Role of PGC-1α in Vascular Regulation: Implications for Atherosclerosis.

Authors:  Andrew O Kadlec; Dawid S Chabowski; Karima Ait-Aissa; David D Gutterman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-06-16       Impact factor: 8.311

Review 9.  Response of vascular mesenchymal stem/progenitor cells to hyperlipidemia.

Authors:  Ting Chen; Yutao Wu; Wenduo Gu; Qingbo Xu
Journal:  Cell Mol Life Sci       Date:  2018-06-26       Impact factor: 9.261

10.  Endothelial CD36 Contributes to Postischemic Brain Injury by Promoting Neutrophil Activation via CSF3.

Authors:  Lidia Garcia-Bonilla; Gianfranco Racchumi; Michelle Murphy; Josef Anrather; Costantino Iadecola
Journal:  J Neurosci       Date:  2015-11-04       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.